Appili Therapeutics Inc. (APLIF) Research

Appili Therapeutics Inc., founded in 2015 and headquartered in Halifax, Canada, is a biopharmaceutical company dedicated to sourcing and progressing innovative medical treatments to address critical unmet needs in infectious diseases. Its comprehensive anti-infective pipeline includes several key candidates: Favipiravir, which targets pandemic influenza and COVID-19; ATI-2307, an antifungal drug currently in clinical trials for conditions like cryptococcal meningitis and invasive candidiasis; ATI-1503, an emerging class of antibiotics specifically designed to combat gram-negative bacteria; ATI-1501, a metronidazole-based antibiotic presented as a taste-masked liquid oral suspension; ATI-1801, a unique topical application of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine aimed at Francisella tularensis. The company also holds a strategic partnership with AiPharma Global Holdings LLC for the continued advancement of Avigan/Reeqonus (favipiravir).

Market snapshot

Symbol
APLIF
Price
$0.01
Day change
0.00%
Market cap
$1.9M
P/E ratio
-0.65x
52-week range
0.009-0.031
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 11 days

Peer companies

  • America Great Health (AAGH)
  • Ayala Pharmaceuticals, Inc. (ADXS)
  • Algernon Pharmaceuticals Inc. (AGNPF)
  • Health Sciences Group, Inc. (HESG)
  • Universal Ibogaine Inc. (IBOGF)
  • Imagion Biosystems Limited (IBXXF)
  • Restart Life Sciences Corp. (NMLSF)
  • Regen BioPharma, Inc. (RGBP)

Open Appili Therapeutics Inc. (APLIF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.